Oncogenicity of the developmental transcription factor Sox9

Cancer Research

Volumn 72, Issue 5, 2012, Pages 1301-1315

  Matheu, Ander ^a,c   Collado, Manuel ^b   Wise, Clare ^a   Manterola, Lorea ^c   Cekaite, Lina ^e   Tye, Angela J ^a   Canamero, Marta ^b   Bujanda, Luis ^d   Schedl, Andreas ^g   Cheah, Kathryn S E ^f   Skotheim, Rolf I ^e   Lothe, Ragnhild A ^e   De Munain, Adolfo Loṕez ^c   Briscoe, James ^a   Serrano, Manuel ^b   Lovell Badge, Robin ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b Centro Nacional de Investigations Oncológicas   (Spain)

^c BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

^g CENTRE DE BIOCHIMIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; TRANSCRIPTION FACTOR SOX9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARCINOGENESIS; CARCINOGENICITY; CELL AGING; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; GENE DOSAGE; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INK4A GENE; MALIGNANT TRANSFORMATION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATOR GENE; SOX9 GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; HUMANS; MICE; MICE, NUDE; SOX9 TRANSCRIPTION FACTOR;

EID: 84857700780     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3660     Document Type: Article

References (61)

1. Sekido R, Lovell-Badge R. Sex determination and SRY: down to a wink and a nudge? Trends Genet 2009;25:19-29.
2. Wegner M. All purpose Sox: the many roles of Sox proteins in gene expression. Int J Biochem Cell Biol 2009;42:381-90.
3. Foster JW, Dominguez-Steglich MA, Guioli S, Kwok C, Weller PA, Stevanovic M, et al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature 1994;372: 525-30. (Pubitemid 24368528)
4. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 2002;16:2813-28. (Pubitemid 35253149)
5. Bishop CE, Whitworth DJ, Qin Y, Agoulnik AI, Agoulnik IU, Harrison WR, et al. A transgenic insertion upstream of sox9 is associated with dominant XX sex reversal in the mouse. Nat Genet 2000;26:490-4.
6. Hanley KP, Oakley F, Sugden S, Wilson DI, Mann DA, Hanley NA. Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis. J Biol Chem 2008;283:14063-71.
7. Pritchett J, Athwal V, Roberts N, Hanley NA, Hanley KP. Understanding the role of SOX9 in acquired diseases: lessons from development. Trends Mol Med 2011;17:166-74.
8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127:2893-917.
9. van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 2009;71:241-60.
10. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50. (Pubitemid 40558990)
11. Radtke F, Clevers H, Riccio O. From gut homeostasis to cancer. Curr Mol Med 2006;6:275-89.
12. Vidal VP, Ortonne N, Schedl A. SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms. J Cutan Pathol 2008;35:373-9. (Pubitemid 351363761)
13. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res 2008;68:1625-30. (Pubitemid 351416545)
14. Jiang SS, Fang WT, Hou YH, Huang SF, Yen BL, Chang JL, et al. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res 2010;16:4363-73.
15. Kordes U, Hagel C. Expression of SOX9 and SOX10 in central neuroepithelial tumor. J Neurooncol 2006;80:151-5. (Pubitemid 44614795)
16. Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, Miyamura Y, et al. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest 2009;119:954-63.
17. Lu B, Fang Y, Xu J, Wang L, Xu F, Xu E, et al. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol 2008;130:897-904.
18. Darido C, Buchert M, Pannequin J, Bastide P, Zalzali H, Mantamadiotis T, et al. Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells. Cancer Res 2008;68:4258-68.
19. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004;166:37-47. (Pubitemid 38931915)
20. Mori-Akiyama Y, van den Born M, van Es JH, Hamilton SR, Adams HP, Zhang J, et al. SOX9 is required for the differentiation of Paneth cells in the intestinal epithelium. Gastroenterology 2007;133:539-46. (Pubitemid 47187347)
21. Furuyama K, Kawaguchi Y, Akiyama H, Horiguchi M, Kodama S, Kuhara T, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet 2011;43:34-41.
22. Bastide P, Darido C, Pannequin J, Kist R, Robine S, Marty-Double C, et al. Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J Cell Biol 2007;178:635-48. (Pubitemid 47267275)
23. Ling S, Chang X, Schultz L, Lee TK, Chaux A, Marchionni L, et al. An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res 2011;71:3812-21.
24. Cheung M, Chaboissier MC, Mynett A, Hirst E, Schedl A, Briscoe J. The transcriptional control of trunk neural crest induction, survival, and delamination. Dev Cell 2005;8:179-92. (Pubitemid 40197735)
25. Matheu A, Pantoja C, Efeyan A, Criado LM, Martin-Caballero J, Flores JM, et al. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev 2004;18:2736-46. (Pubitemid 39507767)
26. Agesen TH, Berg M, Clancy T, Thiis-Evensen E, Cekaite L, Lind GE, et al. CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer. Genes Immun 2011;12:653-62.
27. Sveen A, Agesen TH, Nesbakken A, Rognum TO, Lothe RA, Skotheim RI. Transcriptome instability in colorectal cancer identified by exon microarray analyses: associations with splicing factor expression levels and patient survival. Genome Med 2011;3:32.
28. Berg M, Agesen TH, Thiis-Evensen E, Merok MA, Teixeira MR, Vatn MH, et al. Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Mol Cancer 2010;9:100.
29. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
30. Scott CE, Wynn SL, Sesay A, Cruz C, Cheung M, Gomez Gaviro MV, et al. SOX9 induces and maintains neural stem cells. Nat Neurosci 2010;13:1181-9.
31. Chaboissier MC, Kobayashi A, Vidal VI, Lutzkendorf S, van de Kant HJ, Wegner M, et al. Functional analysis of Sox8 and Sox9 during sex determination in the mouse. Development 2004;131:1891-901. (Pubitemid 38702025)
32. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130:223-33. (Pubitemid 47081143)
33. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46. (Pubitemid 38167315)
34. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology: senescence in premalignant tumours. Nature 2005;436:642. (Pubitemid 41117258)
35. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602. (Pubitemid 27152402)
36. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705. (Pubitemid 46273577)
37. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999;397:164-8. (Pubitemid 29050921)
38. Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ, Li SX, et al. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 2010;136:997-1006.
39. Du J, Li Y, Li J, Zheng J. Polycomb group protein Bmi1 expression in colon cancers predicts the survival. Med Oncol 2010;27:1273-6.
40. Bakos RM, Maier T, Besch R, Mestel DS, Ruzicka T, Sturm RA, et al. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Exp Dermatol 2010;9:e89-94.
41. Flammiger A, Besch R, Cook AL, Maier T, Sturm RA, Berking C. SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells. J Invest Dermatol 2009;129:945-53.
42. Rao P, Fuller GN, Prieto VG. Expression of Sox-9 in metastatic melanoma - a potential diagnostic pitfall. Am J Dermatopathol 2010;32: 262-6.
43. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-11.
44. Lothe RA, Karhu R, Mandahl N, Mertens F, Saeter G, Heim S, et al. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res 1996;56:4778-81. (Pubitemid 26338084)
45. Pezzolo A, Coco S, Raso A, Parodi F, Pistorio A, Valdora F, et al. Loss of 10q26.1-q26.3 in association with 7q34-q36.3 gain or 17q24.3-q25.3 gain predict poor outcome in pediatric medulloblastoma. Cancer Lett 2011;308:215-24.
46. Orsetti B, Courjal F, Cuny M, Rodriguez C, Theillet C. 17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene 1999;18:6262-70.
47. Dimova I, Orsetti B, Negre V, Rouge C, Ursule L, Lasorsa L, et al. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori 2009;95:357-66.
48. Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE, Hsu FC, et al. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate 2008;68:691-7. (Pubitemid 351632941)
49. Huang B, Wang S, Ning Y, Lamb AN, Bartley J. Autosomal XX sex reversal caused by duplication of SOX9. Am J Med Genet 1999;87: 349-53.
50. Kurth I, Klopocki E, Stricker S, van Oosterwijk J, Vanek S, Altmann J, et al. Duplications of noncoding elements 5′ of SOX9 are associated with brachydactyly-anonychia. Nat Genet 2009;41:862-3.
51. Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G, et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 2010;70:979-87.
52. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
53. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 2006;45:31-41. (Pubitemid 46930859)
54. Grinstein E, Mahotka C. Stem cell divisions controlled by the protooncogene BMI-1. J Stem Cells 2009;4:141-6.
55. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J, et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007;12:328-41. (Pubitemid 47539307)
56. Xu CR, Lee S, Ho C, Bommi P, Huang SA, Cheung ST, et al. Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis. Mol Cancer Res 2009;7:1937-45.
57. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008;40:915-20. (Pubitemid 351913652)
58. Tateishi K, Ohta M, Kanai F, Guleng B, Tanaka Y, Asaoka Y, et al. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res 2006;12:6960-6. (Pubitemid 44974489)
59. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007;12:559-71. (Pubitemid 350199071)
60. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010;12:982-92.
61. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004;203:217-24. (Pubitemid 38058689)